Prelude Therapeutics Incorporated Share Price
Equities
PRLD
US74065P1012
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 USD | +0.74% | +9.41% | -4.68% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 223M 18.63B |
---|---|---|---|---|---|
Net income 2024 * | -140M -11.67B | Net income 2025 * | -159M -13.26B | EV / Sales 2024 * | - |
Net cash position 2024 * | 207M 17.29B | Net cash position 2025 * | 161M 13.42B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.01
x | P/E ratio 2025 * |
-2.15
x | Employees | 128 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.07% |
Latest transcript on Prelude Therapeutics Incorporated
1 day | +0.74% | ||
1 week | +9.41% | ||
Current month | -14.14% | ||
1 month | -11.71% | ||
3 months | +13.69% | ||
6 months | +103.50% | ||
Current year | -4.68% |
Managers | Title | Age | Since |
---|---|---|---|
Krishna Vaddi
FOU | Founder | 58 | 01/16/01 |
Bryant Lim
DFI | Director of Finance/CFO | 53 | 01/23/01 |
Jane Huang
PSD | President | 51 | 04/22/04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 25/21/25 |
Paul Friedman
CHM | Chairman | 81 | 01/16/01 |
David Bonita
BRD | Director/Board Member | 48 | 01/16/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 4.07 | +0.74% | 18,553 |
25/24/25 | 4.04 | +4.39% | 115,746 |
24/24/24 | 3.87 | 0.00% | 28,584 |
23/24/23 | 3.87 | +0.52% | 24,900 |
22/24/22 | 3.85 | +3.49% | 50,051 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.68% | 223M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PRLD Stock